个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yungchang Chen[1] ; Hao Sun[2] ; Yanhong Deng[3] ; Yutong Ma[4] ; He Huang[5] ; Yang Liu[6] ; Yaru Zhang[4] ; Hongyu Zhang[7] ; Sheng Ye[8] ; Mingyan E[9] ; Hongqiang Guo[10] ; Mengmeng Wu[4] ; Chunman Wu[4] ; Xingxiang Pu[11] ; Xinggui Chen[12] ; Chaoyong Liang[13] ; Qiuxiang Ou[4] ; Huawei Weng[5] ; Xue Wu[4] ; Yang Shao[4,14] ; Anxin Gu[9] ; Tongyu Lin[1,5] ;
机构： [1]Department of Medical Oncology, Sichuan Cancer Center, Schoolof Medicine, Sichuan Cancer Hospital and Institute, Universityof Electronic Science and Technology of China, No. 55, Section 4, SouthRenmin Road, Sichuan 610041 Chengdu, China [2]Department of Gastrointestinal Cancer Center, Chongqing UniversityCancer Hospital, 400030 Chongqing, China [3]Department of Medical Oncology, The Sixth Affiliated Hospital of SunYat-sen University, 510655 Guangzhou, China [4]Geneseeq Research Institute, Nanjing Geneseeq Technology Inc,210000 Nanjing, China [5]Department of Medical Oncology, State Key Laboratory of Oncologyin Southern China, Collaborative Innovation Center of Cancer Medicine,Sun Yat-sen University Cancer Center, 510060 Guangzhou, China [6]Department of Pathology, Sichuan Cancer Center, School of Medicine,Sichuan Cancer Hospital and Institute, University of Electronic Scienceand Technology of China, 610041 Chengdu, China [7]Department of Medical Oncology, The Fifth Affiliated Hospital of SunYat-sen University, 519000 Zhuhai, China [8]Department of Medical Oncology, The First Affiliated Hospital of SunYat-sen University, 510080 Guangzhou, China [9]Department of Radiation Oncology, Harbin Medical UniversityCancer Hospital, 150 Haping Road, Nangang District, 150040 Harbin,Heilongjiang, China [10]Department of Medical Oncology, The Affiliated Cancer Hospitalof Zhengzhou University, Henan Cancer Hospital, 450008 Zhengzhou, China [11]Department of Thoracic Medical Oncology, Hunan Cancer Hospitaland The Affiliated Cancer Hospital of Xiangya School of Medicine, CentralSouth University, 283 Tongzipo Road, Yuelu District, 410013 Changsha, China [12]Department of Medical Oncology, Cancer Center, Affiliated Hospitalof Guangdong Medical University, 524023 Zhanjiang, China [13]Department of Medical Oncology, Guangxi Medical University CancerHospital, 530021 Nanning, China14 School of Public Health, Nanjing Medical University, 211166 Nanjing,China
出处：
DOI： 10.1186/s40364-022-00443-8
ISSN：

关键词： BRAF Colorectal cancer Next-generation sequencing Prognosis

摘要：
BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups.© 2023. The Author(s).

基金：
Science Foundation of the Postdoctoral Department of Heilongjiang Province (No.LBH-Q21118), Haiyan Research Funding of the Harbin Medical University Cancer Hospital (No. JJZD2021-03), and Program of Science and Technology of Sichuan Province (No.2021YFQ0037).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 医学：研究与实验 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 医学：研究与实验 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY
最新[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Sichuan Cancer Center, Schoolof Medicine, Sichuan Cancer Hospital and Institute, Universityof Electronic Science and Technology of China, No. 55, Section 4, SouthRenmin Road, Sichuan 610041 Chengdu, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Medical Oncology, Sichuan Cancer Center, Schoolof Medicine, Sichuan Cancer Hospital and Institute, Universityof Electronic Science and Technology of China, No. 55, Section 4, SouthRenmin Road, Sichuan 610041 Chengdu, China [5]Department of Medical Oncology, State Key Laboratory of Oncologyin Southern China, Collaborative Innovation Center of Cancer Medicine,Sun Yat-sen University Cancer Center, 510060 Guangzhou, China
推荐引用方式(GB/T 7714)：
Yungchang Chen,Hao Sun,Yanhong Deng,et al.The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses[J].BIOMARKER RESEARCH.2023,11(1):doi:10.1186/s40364-022-00443-8.
APA：
Yungchang Chen,Hao Sun,Yanhong Deng,Yutong Ma,He Huang...&Tongyu Lin.(2023).The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses.BIOMARKER RESEARCH,11,(1)
MLA：
Yungchang Chen,et al."The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses".BIOMARKER RESEARCH 11..1(2023)

相关文献

[1]ERBB2 Mutations as Potential Predictors for Recurrence in Colorectal Serrated Polyps by Targeted Next-Generation Sequencing. [2]Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients [3]Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer [4]Non-invasive plasma testing for CD274 UTR structural variations by next-generation sequencing in cancer [5]Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing. [6]中国前列腺癌患者基因检测专家共识（2018年版） [7]Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas [8]Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer [9]Next generation sequencing of RB1gene for the molecular diagnosis of ethnic minority with retinoblastoma in Yunnan. [10]Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study

资源点击量：46389 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号